More Avecho Biotechnology Limited news
Avecho Biotechnology LimitedASX: AVE

Appendix 4E and Annual Report 31 December 2021

Feb 27, 2022 at 11:12 PM EST · Issued by Avecho Biotechnology Limited

Filed with ASX · Feb 27, 2022 at 11:12 PM EST

On 6ix: 6ix.com/news/appendix-4e-and-annual-report-31-december-2021

Avecho Biotechnology Ltd has released a press release.

View Attachment

6ix hasn’t read this filing yet.

Avecho Biotechnology Limited on 6ix

Story so far

  • Appendix 4E and Annual Report 31 December 2019Mar 2, 2020

Earlier from Avecho Biotechnology

  • AVE license agreement for US recreational cannabis marketFeb 2, 2022
  • December 2021 Quarterly Activities Report & Appendix 4CJan 30, 2022
  • Application for quotation of securities - AVEJan 9, 2022
  • AVE Licenses CBD Soft-Gel to Medterra Pharma for ArthritisDec 20, 2021
  • Positive results from Avechos Phase I trial of CBD soft-gelDec 7, 2021

Later from Avecho Biotechnology

  • Dosing begins in topical CBD pain studyFeb 28, 2022
  • Positive results from AVEs topical CBD pain studyMar 28, 2022
  • March 2022 Quarterly Activities Report & Appendix 4CApr 28, 2022
  • Suspension from Official Quotation - AVEOJun 8, 2022
  • Update on Listed Options and Federal Court ApplicationJul 14, 2022
All Avecho Biotechnology news releases↗

Follow Avecho Biotechnology into a list and get an email when it puts out news.

Follow Avecho Biotechnology
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer